Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents | Zendy

Torbjörn Karlsson | Zendy

Open Access

Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents

Author(s) -

Torbjörn Karlsson

Publication year - 2011

Publication title -

isrn hematology

Language(s) - English

Resource type - Journals

eISSN - 2090-4428

pISSN - 2090-441X

DOI - 10.5402/2011/108397

Subject(s) - medicine , erythropoiesis , anemia , cancer , hematology , iron deficiency , hemoglobin , randomized controlled trial , clinical trial , ineffective erythropoiesis , oncology

During the past decade, intravenous iron supplementation to ESA (erythropoiesis-stimulating agent) therapy has emerged as an option to augment hemoglobin response in anemic cancer patients. In this paper, the results of seven published randomized clinical trials assessing the role of iron supplementation to ESA therapy in the hematology/oncology setting will be discussed. The pathogenetic mechanisms behind functional iron deficiency, a major reason for ESA hyporesponsiveness in cancer, will also be described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research